01—Abstract
Summary
Summary of the 8-K filed January 8, 2024. Cited figures are marked; the original filing is the authoritative source.
Bristol Myers Squibb furnished an investor presentation on January 8, 2024, timed to the J.P.
Morgan Healthcare Conference, under Item 7.01 (Regulation FD). The filing itself contains no new financial results; its substance is management's strategic framing. BMS describes a 'transition period' through 2025, during which it aims to maximize performance from its Legacy Portfolio (about $25Ba of 2023 sales) while facing loss of exclusivity on several major products, Inflation Reduction Act (IRA) pricing pressure, and intensifying competition.
The company says sustainable, top-tier growth is expected from the late 2020s, driven by its Growth Portfolio and a pipeline of 12 registrational-stage and 30+ early-stage assets. Management reaffirmed its previously issued financial targets: a low-to-mid single-digit revenue CAGR from 2020-2025 at constant exchange rates, a low double-digit CAGR excluding Revlimid and Pomalyst, $8Bb-$10B of growth from in-line brands, more than $10B of revenue from the new product portfolio in 2026, an operating margin above 37% through 2025 (excluding future business development), and $25B of non-risk-adjusted sales from the New Product Portfolio by 2030. Business development is positioned as a continued priority, with recent and pending deals including Mirati, Karuna, RayzeBio and SystImmune, all expected to close in the first half of 2024.
These acquisitions are central to the growth thesis but add integration and execution risk. For investors, the key takeaways are the company's dependence on successful execution of its late-stage pipeline (including Breyanzi, Camzyos, Sotyktu, milvexian, KarXT and CD19 NEX T) to offset legacy erosion, and the reliance on pending acquisitions closing on schedule. The presentation contains forward-looking statements and non-GAAP measures and does not provide updated quantitative guidance beyond the reaffirmed targets.
02—Key points
Key Highlights
- Reaffirmed all previously issued financial targets, including a low-to-mid single-digit revenue CAGR (2020-2025) at constant exchange rates and an operating margin above 37% through 2025.
- Management frames 2024-2025 as a 'transition period' focused on maximizing performance from legacy brands while navigating LOE on multiple major products and IRA pricing pressure.
- Targets sustainable, top-tier growth from the late 2020s, supported by a Growth Portfolio of 12 registrational-stage and 30+ early-stage assets.
- Targets more than $10B of revenue from the new product portfolio in 2026 and $25B of non-risk-adjusted sales from the New Product Portfolio by 2030.
- Business development remains a priority; pending acquisitions of Mirati, Karuna, RayzeBio and SystImmune are expected to close in 1H 2024, subject to customary closing conditions.
- Multiple 2024 catalysts highlighted, including Breyanzi CLL/SLL PDUFA in March 2024, KarXT schizophrenia adjunctive data and Sotyktu psoriatic arthritis Phase 3 readouts.
- Notes a 'return to historical guidance practice' and a commitment to 15 consecutive annual dividend increases.
03—Questions
Frequently Asked Questions
Did BMS report new financial results or change its guidance in this filing?
No. The 8-K furnishes an investor presentation for the J.P. Morgan Healthcare Conference. It does not include new quarterly or annual results, and it reaffirms existing financial targets rather than issuing new guidance.
Why is the 2024-2025 period described as a 'transition period'?
BMS faces loss of exclusivity on several major products, IRA-driven pricing pressure, and a more competitive environment in this window. Management is focused on maximizing legacy brand cash flow while building the Growth Portfolio that it expects to drive sustainable growth from the late 2020s.
What are the key risks to the growth thesis?
Key risks include execution on late-stage readouts and approvals, successful integration of recently announced acquisitions (Mirati, Karuna, RayzeBio, SystImmune), pricing and access pressures from the IRA, loss of exclusivity timing, and clinical or regulatory setbacks. The presentation's forward-looking statements caution that results may differ materially.
How much of the growth is expected to come from the new product portfolio?
BMS targets more than $10B of revenue from its new product portfolio in 2026 and $25B of non-risk-adjusted sales from the New Product Portfolio by 2030. These figures are non-risk-adjusted, meaning they assume approval and commercial success and carry significant uncertainty.
What is the company doing about capital allocation and shareholder returns?
BMS emphasizes a strong investment-grade balance sheet, continued dividend growth (15 consecutive annual increases), and industry-leading capital returns over the prior three years, while prioritizing business development through licensing, partnerships and bolt-on acquisitions.
04—Continue